

September 07, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400001

Scrip Code: 532504

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400051

Symbol: NAVINFLUOR

Dear Sir/Madam,

Subject: Intimation of Schedule of Analyst / Institutional Investor Meets

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the officials of Navin Fluorine International Limited ('the Company') will be interacting with Analysts / Investors on September 16 and September 17, 2026. The details are as under:

Date	Conference detail	Mode of Interaction	Type of Interaction
16 th & 17 th September 2026	2026 Jefferies India Forum	Physical	One on One & Group Meeting

Presentation to be made at the Meetings is enclosed. Discussions will be based on publicly available information. Kindly note that changes may happen due to exigencies on the part of Host / Company.

This intimation is also being made available on the Company's website at www.nfil.in

Kindly take this intimation on record.

Thanking you,

For **NAVIN FLUORINE INTERNATIONAL LIMITED**

Niraj B. Mankad

President Legal and Company Secretary





Investor Presentation

5th August 2026

This presentation and the accompanying slides (the “Presentation”), **which have been prepared by Navin Fluorine International Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever.** No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Q1 FY27 – Performance highlights

SALES

Rs. 1,045.1 Cr

+44% YoY

+11% QoQ

Operating EBITDA

Rs. 357.1 Cr

+73% YoY

+11% QoQ

Operating EBITDA Margin

34.2 %

+566 bps YoY

-8 bps QoQ

Operating PBT

Rs. 283.3 Cr

+101% YoY

+13% QoQ

Business Highlights

Y-O-Y REVENUE GROWTH

HPP



33%

Specialty



48%

CDMO




82%

Q1 FY27 – Sustainable growth


Revenues

Rs. Crs




Operating EBITDA

Rs. Crs




Operating PBT

Rs. Crs




PAT

Rs. Crs



Revenue In Rs. Crs




Key Highlights

- ✓ Revenue growth led by volume and higher realisations
- ✓ Pricing environment for HFC continues to be constructive; increasing interest for contractual offtakes in new capacities
- ✓ AHF facility commenced operations in Q4 FY26 and continues to be ramped up
- ✓ Capex for additional HFC capacity equivalent upto 15,000 MTPA of R32 is on track to be commissioned in Q3FY27

GEOGRAPHIC MIX



Revenue In Rs. Crs




Key Highlights

- ✓ Sustained growth underpinned by strong order visibility
- ✓ Product pipeline continues to remain strong, with meaningful scale-up across existing molecules and a strong line-up of new launches
- ✓ Chemours project is targeted for completion by end of Q2 FY27
- ✓ De-bottlenecking MPP capacity at Dahej is on track for commissioning in Q3 FY27

GEOGRAPHIC MIX



Revenue In Rs. Crs



GEOGRAPHIC MIX



02%



98%

Key Highlights

- ✓ Strong momentum continues, backed by order book
- ✓ Continued deeper engagement with European CDMO major. Supported by:
 - Increasing demand for existing molecule
 - Expanding our footprint in their supply chain
- ✓ Board had already approved cGMP4 capex of Rs. 288 Crs in Feb 24
 - Phase I capex operationalized in Q3 FY26. Initiated today, Phase II - cGMP4 capex of Rs. 125 Crs is expected to operationalize by Q4 FY27
- ✓ Strategy -in-action :
 - Balanced portfolio with good mix of late/commercial and early-stage molecules
 - Increasing footprint across range of promising therapeutic areas with global innovators- Oncology, Respiratory, Cardiovascular, Neurology and Animal health

Incubating advanced materials

Putting our strategy into action for developing a new high growth, high margin business vertical for the future. Building on core fluorination capabilities, the vertical will focus on niche applications in high growth sunrise sector – Data Centers, Electronics, Defence & Semiconductors.

ADOPTION CAPACITIES Capex : Rs. 90 Crs		<i>Setting up adoption capacities to commercialise product pipeline.</i>
CHEMOURS PROJECT Capex : Rs. 120 Crs		<i>Setting up Initial commercial capacity to enable adoption of innovative liquid cooling product</i>
DRDO		<i>Driving AtmaNirbhar Bharat through DRDO TDF project for indigenous process development for a critical defence material</i>

	Advanced Materials	cGMP4*
Capex Details	To set up adoption capacities for Advanced Materials	Initiated today, Phase II - cGMP4 capex of Rs. 125 Crs
Capex Rational	• Incubate new value accretive business vertical as a future growth driver • Augment capability and cater to commercial scale qualification supplies	• Increasing demand for existing molecule of European CDMO major. • Expanding our footprint in their supply chain
Amount & Completion Date	• Capex of Rs. 90 Crs • Completion by Q2 FY28	• Capex cost of phase II - Rs.125 Crs • Completion by Q4 FY27
Peak Revenue Potential	Access future growth opportunity	An asset turnover of ~3x

* Board had already approved cGMP4 capex of Rs. 288 Crs in Feb 24

Ongoing capex program

	HFC	MPP	Chemours Project	Renewable power project
 Capex Details	Additional HFC capacity equivalent upto 15,000 MTPA of R32	De-bottlenecking MPP capacity at Dahej to support launch of new molecule for a global innovator	Initial commercial capacity for manufacturing to enable adoption of innovative liquid cooling product	Investment in SPV for setting up of hybrid power plant
 Capex Rational	Constructive global demand-supply environment driven by transition to low GWP gasses and increasing RAC and blends demand in India and export market	- Strong projections received from global innovator to participate in their growth Purchase order received for CY26	For expanding footprint in the emerging and innovative Advanced Materials products	Reinforces sustainability through increased renewable energy adoption and continued progress toward decarbonization goals - This project will lead to over 60% of energy needs met from renewable sources
Amount & Completion	- Capex of Rs. 236.5 Crs to be funded by internal accruals. - Project expected to be commissioned by Q3FY27	- Capex of Rs. 75 Crs to be funded by internal accruals. - Targeted commissioning by Q3FY27	Capex of Rs. 120 Crs, with 35 % funded by customer; balance through internal accruals Targeted commissioning by Q2 FY27	Investment of Rs. 15.73 Crs for 14.9 MW of Hybrid capacity across NFIL & NFASL
Peak Revenue Potential	~ Rs. 600-825 Crs per annum	~ Rs. 140-160 Crs per annum	Under Confidentiality	

Consolidated Profitability Statement

Particulars (Rs. Crs.)	Q1 FY27	Q1 FY26	Y-o-Y Change	Q4 FY26	Q-o-Q Change	FY26	FY25	Y-o-Y Change
Net Revenue from Operations	1,045.08	725.40	44%	937.71	11%	3,313.90	2,349.38	41%
Raw Material	449.75	307.71		388.07		1,376.40	1,038.62	
Employee Expenses	86.57	77.57		81.01		307.27	296.67	
Other Expenses	151.69	133.33		147.48		548.55	480.37	
Operating EBITDA	357.07	206.79	73%	321.15	11%	1,081.68	533.72	103%
Operating EBITDA Margin	34.2%	28.5%	566 bps	34.2%	-8 bps	32.6%	22.7%	992 Bps
Interest Expenses	32.12	30.35		28.94		117.85	77.93	
Depreciation	41.68	35.24		41.22		149.20	119.43	
Operating PBT	283.27	141.20	101%	250.99	13%	814.63	336.36	142%
Operating PBT Margin	27.1%	19.5%	764 bps	26.8%	34 bps	24.6%	14.3%	1027 Bps
Other Income	35.09	13.91		17.59		65.29	43.73	
Exceptional Item	0.00	0.00		13.72		(6.75)	0.00	
Profit before tax	318.36	155.11	105%	282.30	13%	873.17	380.09	130%
Tax	75.05	37.94		69.68		209.61	91.49	
Profit After Tax	243.31	117.17	108%	212.62	14%	663.56	288.60	130%
(Loss) from Associates and joint ventures (net)	0.00	(0.01)		0.00		(0.01)	(0.02)	
Other Comprehensive Income	243.31	117.16		212.62		670.32	288.58	130%
(a) Items that will not be reclassified to Profit & Loss (net of tax)	0.36	(1.27)		(1.37)		(3.29)	1.35	
(b) Items that may be reclassified to profit and loss	(0.13)	1.71		1.71		4.46	1.51	
Total Comprehensive income for the Period	243.54	117.60	107%	212.96	14%	664.72	291.44	128%

Standalone Profitability Statement

Particulars (Rs. Crs.)	Q1 FY27	Q1 FY26	Y-o-Y Change	Q4 FY26	Q-o-Q Change	FY26	FY25	Y-o-Y Change
Net Revenue from Operations	694.68	542.95	28%	626.51	11%	2,301.84	1,686.81	36%
Raw Material	292.40	239.44		276.24		1,026.29	777.70	
Employee Expenses	62.43	54.61		59.12		220.94	217.91	
Other Expenses	94.87	94.70		107.59		391.05	352.37	
Operating EBITDA	244.98	154.20	59%	183.56	33%	663.56	338.83	96%
Operating EBITDA Margin	35.3%	28.4%	686 Bps	29.3%	597 Bps	28.8%	20.1%	874 Bps
Interest Expenses	4.88	0.84		2.80		7.88	3.19	
Depreciation	21.10	18.80		22.32		80.02	69.88	
Operating PBT	219.00	134.56	63%	158.44	38%	575.66	265.76	117%
Operating PBT Margin	31.5%	24.8%	674 Bps	25.3%	624 Bps	25.0%	15.8%	925 Bps
Other Income	35.84	14.87		19.34		87.53	55.54	
Exceptional Item	0.00	0.00		11.91		(6.93)	0.00	
Profit before tax	254.84	149.43	71%	189.69	34%	656.26	321.30	104%
Tax	64.20	36.67		54.66		168.59	79.37	
Profit After Tax	190.64	112.76	69%	135.03	41%	487.67	241.93	102%
(Loss) from Associates and joint ventures (net)	0	0		0		0	0	
Other Comprehensive Income	190.64	112.76		135.03		487.67	241.93	
Items that will not be reclassified to Profit & Loss (net of tax)	0.27	(1.08)		(1.33)		(2.90)	1.52	
Total Comprehensive income for the Period	190.91	111.68	71%	133.70	43%	484.77	243.45	99%

Company Overview





Because innovation creates its greatest impact when it is guided by purpose.

Innovation has been at the heart of Navin Fluorine's nearly six-decade journey. From pioneering fluorochemistry capabilities to developing advanced materials, pharmaceutical solutions, specialty chemicals and next-generation technologies, every innovation redefines how we create meaningful **value for customers, industries and society**

INNOVATING >>>
with **PURPOSE**

PRESENCE ACROSS

3

Geographies

3

Business Verticals

3

R & D Centres

4

Countries

4

Manufacturing
Units

OUR BUSINESSES



High Performance
Products (HPP)




Speciality
Chemicals



Contract Development
and Manufacturing
Organisation (CDMO)

3P STRATEGY



Demonstrated excellence across businesses



6 Decades

of expertise in fluorine chemistries



One of the first

companies to establish a refrigerant business in India



Only Indian

manufacturer of hydrofluoroolefins (HFO)



Amongst India's largest

producers of inorganic chemicals -

- anhydrous hydrofluoric acid (AHF)
- and diluted hydrofluoric acid (HF)



One of the largest

BF₃ manufacturers globally



World-class CDMO

cGMP compliant facilities catering to global pharma innovators



Amongst the **most trusted global players** in specialty fluorochemicals



One of the largest

Integrated Specialty Fluorochemical companies in India



Proven capabilities for fluorination chemistries with

precision-driven expertise from research to commercial scale

Our winning edge

>>> Building Trusted Solutions for Life



**Integrated
Fluorine
Provider**



Reputed Brand



Mafron

Mafron®



Rich Legacy



**Strategic
Partnerships**



**Committed to
ESG**



**Diversified
Portfolio**



**Prominent
Clientele**



**World-class
Infrastructure**



**Credible
Certifications**



**Strong Global
Presence**




**Thriving
Workforce**

Rooted in 3P strategy



Products

Diversified portfolio that includes fluorine based intermediates, specialty chemicals and inorganic chemicals



Platform

Prioritising owning of specific technologies and chemistries that serve as building blocks (BB) for various business applications
Utilising capabilities to diversify product pipeline and reinforce technology leadership



Partnerships

Strategic multiyear partnerships to strengthen global supply chain presence alongside industry innovators and leaders Leveraging partner expertise and resources to extend reach and impact

3P Focus

Capacity
Expansion

Building Scalable
Platforms

Nurturing Long-
Team Partnerships

Strengthening innovation and R&D capabilities

Key R&D Differentiators

RESEARCH FOCUSED

Focussed on research-driven innovation to develop complex KSMs for global pharma and biotech innovators

DEEP INDUSTRY EXPERTISE

Nearly 6 decades of fluorine chemistry experience supported by the latest technology platforms, delivering multi-step complex, value added products for our partners.

STRATEGIC R&D INVESTMENT

Strong management focus on emerging trends through ongoing R&D investments to deliver a robust, innovative product pipeline

BACKWARD INTEGRATION

Integrating high-end fluorine reagents enables cost-effective KSM developments and strengthens relationships with global pharma and biotech innovators.

COLLABORATIVE EXCELLENCE

Synergistic tie-ups with customers and technology teams ensure timely and efficient delivery of commitments in a time sensitive industry.

DIGITAL TRANSFORMATION

Advancing digitalisation through the planned implementation of Electronic Lab Notebooks (ELN) and LIMS to improve efficiency, traceability and compliance.

3 Modern R&D Centres

Navin Research & Innovation Centre, Surat, Gujarat

- Undertakes ongoing R&D investments in core infrastructure and cutting-edge analytical equipment
- Houses 65 chemists and 40 engineers in the Technology and Design
- Exhibited commercial-scale capabilities across both fluorination and non fluorinated chemistries
- Develops and expands fluorinated specialty chemicals beyond traditional verticals

Navin Molecular R&D Centre, Dewas, MP and Runcorn, Manchester

- Focus on contract development and technology transfer of predominantly preclinical and clinical candidates in partnership with global pharmaceutical and biotech partners
- Comprise 70 team members (For Dewas R&D) and 18 team members (For Runcorn MOL R&D)
- Have successfully executed phase driven projects from pre-clinical to Phase III and commercial molecule to customers


Total R&D spend in FY 2025-26

Rs 48.71 Crs

Committed to

Sustainable Value Creation

At Navin Fluorine, sustainability defines how we operate and grow. Our structured Environment, Social and Governance (ESG) framework is guided by the principles of Responsible Care (RC) and Pharmaceutical Supply Chain Initiative (PSCI). With accountability, transparency and long-term stakeholder value creation at its core, it ensures that every decision made and innovation pursued creates a positive impact on our planet, people and communities.



Progress towards our sustainability goals

ESG Goals

Environmental

100%

compliance with EPR requirements for Plastic Packaging Materials by 2025

30%

reduction in carbon emissions by 2030 from the base year 2023

50%

use of renewable electricity by 2030

Engagement with
100%

key value chain partners by 2030

UN SDGs Impacted



Social

10%

diversity in the Company employees by 2030

25%

gender diversity in leadership teams by 2030

25%

gender diversity across the Board by 2030

UN SDGs Impacted



Governance

100%

resolution of complaints

ZERO

cases of corruption and bribery

UN SDGs Impacted



Progress on ESG Targets in FY 2025-26

Environmental

100%

compliance achieved with respect to EPR requirements for Plastic Packaging Materials

Increase of 11.1%

in specific carbon emissions in tCO₂/tonne of production

12.15%

usage of renewable electricity in 2026

Engaged with
30%

of value chain partners in 2026

Social

3.94%

workplace diversity in 2026

0%

gender diversity in leadership teams in 2026

10%

gender diversity in the Board of Directors

Governance

89.24%

% resolution of complaints in 2026

ZERO

cases of corruption and bribery in 2026

Governance framework

Board Demographics

Highly engaged Board

actively involved in NFIL's strategic transformation



58 years median Directors' age




Meetings during FY 2026

17 Board Committee

8 Board


Highly Experienced Board to chair Committees

Audit Committee	CSR Committee
Nomination & Remuneration Committee	Stakeholders' Relationship Committee
Risk Management Committee	
Fund Raising Committee*	
ESG Steering Committee	




7 Directors inducted since FY22

Board Independence



6 of 10 Directors are Independent



8 of 10 Directors are Non-Executive



1 Woman Director (Independent) on the Board

The Chairman and Managing Director have historically been **separate positions**

335+ Years of Consolidated experience of the Board

* Fund Raising Committee dissolved w.e.f. February 09, 2026

Mr. Vishad P. Mafatlal (Chairman)

He is an accomplished industrialist with varied experience of 29+ years in the field of textiles and chemicals. He has a Bachelor of Science degree in Economics from the University of Pennsylvania's Wharton School.

Mr. Atul K. Srivastava (Independent Director)

He has an experience of over 49 years in large corporates, in the areas of Finance, Accounting, Taxation and Commerce. He is a Science Graduate and a Fellow Chartered Accountant - B. Sc (Hons), FCA.

Mr. Sunil S. Lalbhai (Non-Executive Non-Independent Director)

He is an industrialist having varied experience of over 36 years in chemicals and general management. He is a science graduate and holds M.S degree in chemistry from USA and also M.S degree in economic planning & policy from the Boston University of USA.

Mr. Ashok U. Sinha (Independent Director)

He has a wealth of experience, competencies and expertise from his leadership journey at Bharat Petroleum Corporation Ltd. He has a BTech in Electrical Engineering from IIT, Kanpur, and a Post Graduate Diploma in Management from IIM, Bangalore, with specialisation in Finance.

Mr. Sujal A. Shah (Independent Director)

He has an experience of over 33 years in the fields of Valuation, Due Diligence, Corporate Restructuring, Audit and Advisory. He is a commerce graduate and member of the Institute of Chartered Accountants of India.

Mr. Kartikeya A. Dube (Independent Director)

Mr. Dube has more than 30 years of diverse and rich experience in business, finance, governance, risk, M&A, fund raising, procurement, government affairs, cross border investment/transaction strategy and structures, regulatory framework, life cycle transactions, exchange control and investment regulations, etc. He is a Chartered Accountant and a Bachelor of Commerce. He has attended various leadership programs including INSEAD.

Ms. Apurva S. Purohit (Independent Director)

She is a prominent Indian Business leader with over 33 years of experience in the media and entertainment industry. She has managed a diverse portfolio of businesses in partnership with private equity players and promoters, from early stage businesses to mature ones. She has a postgraduate diploma in management from IIM, Bangalore.

Mr. Abhijit J. Joshi (Independent Director)

Mr. Joshi is the Founding and Managing Partner of Veritas Legal being regarded among Asia's Top 15 Private Wealth and M&A Lawyers with a legal career spanning 3 decades. Over the years, he has advised various business houses, promoter families, global conglomerates and large private equity houses across industry sectors on numerous complex deals and cases. He is a dual-qualified solicitor in India and England.

Mr. Sudhir R. Deo (Non-Executive Non-Independent Director)

Mr. Deo has 45 years of association with Arvind Mafatlal Group (AMG), retired as Managing Director of NOCIL in July 2023. He has headed multiple mandates of the business including Manufacturing, Technology, Research, Strategy, Marketing and Supply Chain. He is an expert in ESG and Sustainability, focusing on implementation to elevate business value. He holds an M. Tech. in Chemical Engineering from IIT Kanpur.

Mr. Nitin G. Kulkarni (Managing Director)

Mr. Kulkarni has over 3 decades of rich experience across the specialty chemicals value chain, specifically covering fluoro-chemicals and CDMO. He is a highly respected leader with a proven track record of: driving growth, establishing new business verticals, embedding manufacturing excellence, and execution of large projects, both brownfield and greenfield. He is also passionate about HSE and sustainability. He holds a Masters degree in Organic Chemistry from the University of Mumbai.



Reported NO

- ✓ Auditor qualification against the Company
- ✓ Re-statements of financial statements
- ✓ Allegations of financial imprudence
- ✓ Defaults for repayments, creditors and dividends



Structured policies and processes addressed investor grievances



Accepted all the resolutions proposed by the Board to shareholders



Employed a rigorous Board evaluation policy; Board comprised eminent members



Implemented an active succession pipeline for critical roles and the Board



Carried out an Internal audit through an independent audit firm reporting directly to the Audit Committee



Implemented two ESOP plans

Composition of the Statutory Committees as on March 31, 2026

Out of 4 Members of the **Audit Committee**, 3 are Independent and 1 Non-Executive

Out of 3 Members of **Nomination and Remuneration Committee**, 2 are Independent and 1 Non-Executive

Out of 3 Members of **Stakeholders' Relationship Committee**, 2 are Independent and 1 Executive

Out of 3 Members of the **Corporate Social Responsibility Committee**, 1 is Independent, 1 Executive and 1 Non-Executive

Out of 6 Members of the **Risk Management Committee**, 1 is Independent, 2 are Executive, 1 is Non-Executive and 2 are Non-Board Members

Creating lasting social impact through CSR

“The intelligent way to be selfish is to work for the welfare of others”

The Dalai Lama

CSR FOCUS AREAS



Health



Sports



Sustainable Livelihood



Education



Skill Development



Animal Care



Other Social Causes



SHRI SADGURU SEVA SANGH TRUST



OLYMPIC GOLD QUEST



BLIND PEOPLE'S ASSOCIATION



SHAKTI FOUNDATION



CHARUTAR AROGYA MANDAL'S SHRI KRISHNA HOSPITAL




SIR J. J. HOSPITAL

Rs. 8.72 Crs total CSR spend in FY 2025-26

Track record of progressive dividends

Dividend as % of Face Value



* On standalone basis

Thank
you

For further information, please contact:



Navin Fluorine International Ltd.

CIN : L24110MH1998PLC115499

Mr. Anish Ganatra

Chief Financial Officer

anish.ganatra@nfil.in

www.nfil.in

Investor Relations Advisors:



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services

Ms. Payal Dave

payal.dave@in.mpms.mufig.com

Ms. Pooja Swami

pooja.swami@in.mpms.mufig.com

